1.
Savastano C, Lombardi F. Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs: Risposta alla combinazione Lapatinib-Capecitabina in giovane paziente con recidiva di carcinoma della mammella HER2-positivo refrattario a due linee di terapia con farmaci anti-HER2. AboutOpen [Internet]. 2018 Oct. 12 [cited 2024 Jul. 3];4(1):162-5. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/135